phase i/ii trial of ep0031, a next generation selective ret inhibitor
Published 1 year ago • 348 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:12
ellipses pharma: ep0031, next generation selective ret inhibitor
-
6:08
next-generation selective ret inhibitor shows initial promise with ret-altered solid tumours
-
1:22
ellipses pharma: ep0031 in transforming the landscape of ret-altered cancer
-
1:35
#esmo21 highlights on a phase i of dual raf/mek inhibitor fak inhibitor in ovarian cancer (frame)
-
31:29
a bispecific sniper™️ demo preclinical efficacy through the selective elimination of tumor tregs
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
4:34
lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
5:31
pairing experience with expertise – how listening could accelerate cancer treatment
-
20:26
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (2 of 2)
-
3:24
ic rf immunity overview
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
1:13
what is the difference between phase 1, phase 2, and phase 3 trials? #aml
-
0:57
what the future holds for antibodies in treating nsclc
-
1:29
dr. finn on the phase iii paloma-2 trial in er breast cancer
-
5:38
proof-hd: phase iii trial of oral s1r agonist pridopidine for the treatment of huntington’s disease
-
2:45
paloma-3: phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
-
13:49
transcatheter edge-to-edge repair for treatment of tricuspid regurgitation: present and future
-
6:04
percutaneous edge-to-edge repair for tricuspid regurgitation: 1-year outcomes from triluminate trial
-
1:41
dr. richard finn describes the phase iii trial of palbociclib for breast cancer
-
0:31
tms-30i